Prospective PRO/QoL Registry for Patients With Bone Metastases of Breast or Prostate Cancer
- Conditions
- Prostate CancerBreast CancerBone Metastases
- First Posted Date
- 2015-04-07
- Last Posted Date
- 2020-09-10
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 500
- Registration Number
- NCT02410044
- Locations
- 🇩🇪
Multiple sites all over Germany, Multiple Locations, Germany
Bone Pain Score Validation Initiative
- Conditions
- Bone Metastasis
- First Posted Date
- 2014-11-18
- Last Posted Date
- 2018-08-10
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 370
- Registration Number
- NCT02293642
- Locations
- 🇩🇪
Multiple Sites All Over Germany, Multiple Locations, Germany
Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab
- Conditions
- Breast Cancer RecurrentHormone Receptor Positive Malignant Neoplasm of BreastHER2/Neu-negative Carcinoma of Breast
- Interventions
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 85
- Registration Number
- NCT02248571
- Locations
- 🇩🇪
iOMEDICO AG, Freiburg, Baden-Wuerttemberg, Germany
Tumor Registry Pancreatic Cancer
- Conditions
- Pancreas Cancer
- First Posted Date
- 2014-03-17
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 2325
- Registration Number
- NCT02089269
- Locations
- 🇩🇪
iOMEDICO, Freiburg, BW, Germany
Non-interventional Study With Pomalidomide (Imnovid®)
- Conditions
- Multiple Myeloma
- First Posted Date
- 2014-03-03
- Last Posted Date
- 2022-08-12
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 151
- Registration Number
- NCT02075996
- Locations
- 🇩🇪
iOMEDICO AG, Freiburg, Baden-Wuerttemberg, Germany
Clinical Tumor Anemia Registry (TAR)
- Conditions
- Anemia
- First Posted Date
- 2013-02-21
- Last Posted Date
- 2016-02-29
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 1018
- Registration Number
- NCT01795690
- Locations
- 🇩🇪
iOMEDICO, Freiburg, Germany
Non-interventional Study With Nab-Paclitaxel (Abraxane®)
- Conditions
- Metastatic Breast Cancer
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2018-06-20
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 705
- Registration Number
- NCT01689610
- Locations
- 🇩🇪
iOMEDICO AG, Freiburg, Baden-Wuerttemberg, Germany
First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
- Conditions
- Locally Advanced and/or Metastatic Renal Cell CarcinomaCarcinoma, Renal CellClear-cell Metastatic Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2017-08-23
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 44
- Registration Number
- NCT01521715
- Locations
- 🇩🇪
Urolog. Klinik im Waldkrankenhaus St. Marien, Friedrich-Alexander-Universität, Erlangen, Germany
🇩🇪Universitätsklinikum Essen, Klinik f. Urologie, Essen, Germany
🇩🇪Medizinisches Versorgungszentrum (MVZ) Osthessen GmbH, Fulda, Germany
Tumour Registry Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2011-05-11
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 4500
- Registration Number
- NCT01351584
Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)
- Conditions
- Metastatic Renal Cell CarcinomaFailure of Exactly One Prior VEGF-targeted Therapy
- Interventions
- First Posted Date
- 2010-12-24
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 64
- Registration Number
- NCT01266837
- Locations
- 🇩🇪
Klinik für Innere Medizin (Tumorforschung), Universitätsklinikum Essen, Essen, Germany
🇩🇪Urologie - Waldkrankenhaus St. Marien, Erlangen, Germany
🇩🇪Klinik und Poliklinik für Urologie , Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden, Dresden, Germany